Growth Metrics

Axsome Therapeutics (AXSM) Change in Cash (2022 - 2026)

Axsome Therapeutics' Change in Cash history spans 5 years, with the latest figure at -$17.8 million for Q1 2026.

  • On a quarterly basis, Change in Cash fell 23.43% to -$17.8 million in Q1 2026 year-over-year; TTM through Mar 2026 was $4.2 million, a 113.74% increase, with the full-year FY2025 number at $7.6 million, up 110.7% from a year prior.
  • Change in Cash hit -$17.8 million in Q1 2026 for Axsome Therapeutics, down from -$2.3 million in the prior quarter.
  • Over the last five years, Change in Cash for AXSM hit a ceiling of $190.6 million in Q2 2023 and a floor of -$54.8 million in Q1 2024.
  • Historically, Change in Cash has averaged $12.9 million across 5 years, with a median of -$11.3 million in 2022.
  • Biggest five-year swings in Change in Cash: skyrocketed 2687.71% in 2023 and later crashed 219.88% in 2024.
  • Tracing AXSM's Change in Cash over 5 years: stood at -$26.7 million in 2022, then dropped by 13.84% to -$30.4 million in 2023, then soared by 60.53% to -$12.0 million in 2024, then skyrocketed by 80.49% to -$2.3 million in 2025, then tumbled by 662.16% to -$17.8 million in 2026.
  • Business Quant data shows Change in Cash for AXSM at -$17.8 million in Q1 2026, -$2.3 million in Q4 2025, and $22.3 million in Q3 2025.